 On April 27, three top managers of Hepion Pharmaceuticals bought company shares on the same day. Vincent Lopriore (Chairman of the Board) — 6.25 million shares, Gary Stetz (CEO) — 1.25 million, plus a third insider. All three on the same day, at $0.04 per share. Lopriore's stake increased by 125%. This is not just an insider trade. It is a synchronized buying spree — when several people inside a company simultaneously bet their money on the same outcome. Such events are rare and almost always mean that the team sees a gap between the real value of the business and what the market shows. The macroeconomic context makes this signal even louder. The central bank rate of 14.5% is not an abstract number. It means that expensive money is squeezing capital out of overheated sectors, and smart money is looking for assets that the market has undervalued. Micro-caps like HEPA are classic candidates: low liquidity, high volatility, maximum potential for those who see the full picture. The problem is that OpenInsider data comes with a delay. Form 4 enters the system — and then you have to monitor dozens of companies yourself, match trades, check the purchase history of specific managers. This takes an hour of work. Or 14 seconds, if you have an AI agent that analyzes already published data and overlays it with macroeconomic context. ASI Biont analyzes insider trades in seconds — sees patterns of synchronized purchases, checks them against the central bank rate, industry indices, and the history of specific managers. You get not just "who bought how much," but a ready conclusion: why this matters right now. Three Hepion insiders did not choose the same date by chance. They see something that is not yet in the news. The question is whether you will see it too. Get 1500 tokens to start: asibiont.com